A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis.
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 09 May 2017 According to a FibroGen media release, NDA submission in China is targeted in the third quarter of 2017.
- 14 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History